NCT03765749

Brief Summary

Empirical antibiotic and outcome in Community-onset Bacteremia Caused by third generation cephalosporin resistant Enterobacteriaceae

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 22, 2018

Completed
8 months until next milestone

Study Start

First participant enrolled

November 22, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 5, 2018

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

April 19, 2022

Status Verified

April 1, 2022

Enrollment Period

3.1 years

First QC Date

March 22, 2018

Last Update Submit

April 18, 2022

Conditions

Bacteremia

Outcome Measures

Primary Outcomes (1)

  • Mortality rate among community-onset bacteremia caused by third generation cephalosporin resistant enterobacteriaceae

    January 2018 - march 2019

Study Arms (2)

Community onset 3rd generation cephalosporin resistant entero

Patient with Community onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received inappropriate Antibiotic

Nosocomial onset 3rd generation cephalosporin resistant ente

Patient with Nosocomial onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received appropriate Antibiotic

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with community-onset bacteremia caused by third generation cephalosporin resistant enterobacteriaceae. Age \> 18 years

You may qualify if:

  • Patient with Community-onset Bacteremia Caused by third generation cephalosporin resistant Enterobacteriaceae. Age \> 18 years

You may not qualify if:

  • Pregnancy
  • Polymicrobial infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Worapong Nasomsong

Bangkok, 10400, Thailand

Location

Related Publications (1)

  • Nasomsong W, Changpradub D, Vasikasin V. Impact of Inappropriate Empirical Antibiotic on Outcomes in Community-acquired Third Generation Cephalosporin Resistant Enterobacterales Bacteremia. Infect Chemother. 2022 Dec;54(4):722-732. doi: 10.3947/ic.2022.0096.

    PMID: 36596682DERIVED

MeSH Terms

Conditions

Bacteremia

Condition Hierarchy (Ancestors)

Bacterial InfectionsBacterial Infections and MycosesInfectionsSepsisSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 22, 2018

First Posted

December 5, 2018

Study Start

November 22, 2018

Primary Completion

December 31, 2021

Study Completion

December 31, 2021

Last Updated

April 19, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations

TH(1)